5625-65-0

Usage

InChI:InChI=1/C22H20N2O4S/c1-4-28-20-10-14(5-7-18(20)25)9-16(12-23)22-24-17(13-29-22)15-6-8-19(26-2)21(11-15)27-3/h5-11,13,24H,4H2,1-3H3/b14-9+,22-16+

Upstream product

• 5454-83-1 5-bromovaleric acid methyl ester 
• 1369391-14-9 C₁₅H₂₈N₂O₄ 
• 7531-55-7 ethyl 4-(5-hydroxypentyl)piperazine-1-carboxylate 
• 34626-51-2 5-bromopentan-1-ol 

Downstream Products

• 1379668-05-9 2-{4-[5-(4-methoxyphenoxy)pentyl]-piperazin-1-yl}thiazole 
• 1379668-06-0 2-(4-(5-(4-ethoxyphenoxy)pentyl)piperazin-1-yl)thiazole 

Relevant academic research and scientific papers

THIAZOLAMINE DERIVATIVE AND USE THEREOF AS ANTI-PICORNAVIRAL INFECTION MEDICAMENT

Disclosed is as a substituted thiazolamine derivative represented by Formula I or a pharmaceutically acceptable salt thereof or a hydrate thereof (the definitions of each group in the formula are as presented in the description), and the application there

Novel substituted heteroaromatic piperazine and piperidine derivatives as inhibitors of human enterovirus 71 and coxsackievirus A16

A series of substituted heteroaromatic piperazine and piperidine derivatives were found through virtual screening based on the structure of human enterovirus 71 capsid protein VP1. The preliminary biological evaluation revealed that compounds 8e and 9e have potent activity against EV71 and Coxsackievirus A16 with low cytotoxicity.

Design and synthesis of novel sulfonamide-containing bradykinin hB 2 receptor antagonists. Synthesis and structure-relationships of α,α-tetrahydropyranylglycine

A series of α,α-cycloalkylglycine sulfonamide compounds of general formula 1 has previously been identified by our group as selective human B2(hB2) receptor antagonists. Here we report the in vitro and in vivo BK antagonist activity

Pharmacophore-based design, synthesis, and biological evaluation of novel chloro-pyridazine piperazines as human rhinovirus (HRV-3) inhibitors

A series of chloro-pyridazine piperazines were developed based on the structure of human rhinovirus (HRV) capsid-binding inhibitors with proven activity using a pharmacophore model. A preliminary evaluation demonstrated potent activity against HRV-3 with low cytotoxicity. A docking analysis indicated that 8a could fit into, and form tight interactions (e.g., H-bonds, σ-π effect) with the active site in VP1.